IL147477A - Preparation of medication comprising citicoline together with a second pharmaceutical agent for protecting brain tissue from infraction following ischemia - Google Patents
Preparation of medication comprising citicoline together with a second pharmaceutical agent for protecting brain tissue from infraction following ischemiaInfo
- Publication number
- IL147477A IL147477A IL147477A IL14747796A IL147477A IL 147477 A IL147477 A IL 147477A IL 147477 A IL147477 A IL 147477A IL 14747796 A IL14747796 A IL 14747796A IL 147477 A IL147477 A IL 147477A
- Authority
- IL
- Israel
- Prior art keywords
- citicoline
- agents
- ischemia
- therapeutic agent
- salt
- Prior art date
Links
- RZZPDXZPRHQOCG-OJAKKHQRSA-M CDP-choline(1-) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-M 0.000 title claims abstract 16
- 229960001284 citicoline Drugs 0.000 title claims abstract 16
- 239000003814 drug Substances 0.000 title claims 16
- 208000028867 ischemia Diseases 0.000 title claims 12
- 210000005013 brain tissue Anatomy 0.000 title claims 5
- 229940079593 drug Drugs 0.000 title 1
- 239000008177 pharmaceutical agent Substances 0.000 title 1
- 206010008118 cerebral infarction Diseases 0.000 claims abstract 8
- 208000026106 cerebrovascular disease Diseases 0.000 claims abstract 5
- 201000006474 Brain Ischemia Diseases 0.000 claims abstract 3
- 206010008120 Cerebral ischaemia Diseases 0.000 claims abstract 3
- 206010019196 Head injury Diseases 0.000 claims abstract 3
- 208000006011 Stroke Diseases 0.000 claims abstract 3
- 229940124597 therapeutic agent Drugs 0.000 claims 13
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 claims 12
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 claims 12
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 claims 12
- 239000003795 chemical substances by application Substances 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 9
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical group CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 7
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- VOBNSQKMDIOJTQ-UHFFFAOYSA-N 2-aminoethyl phosphono hydrogen phosphate Chemical compound NCCOP(O)(=O)OP(O)(O)=O VOBNSQKMDIOJTQ-UHFFFAOYSA-N 0.000 claims 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims 4
- 239000003146 anticoagulant agent Substances 0.000 claims 4
- 230000000324 neuroprotective effect Effects 0.000 claims 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims 2
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 229940123457 Free radical scavenger Drugs 0.000 claims 2
- 108010023197 Streptokinase Proteins 0.000 claims 2
- 108050006955 Tissue-type plasminogen activator Proteins 0.000 claims 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims 2
- 230000002253 anti-ischaemic effect Effects 0.000 claims 2
- 229940127090 anticoagulant agent Drugs 0.000 claims 2
- 229940127218 antiplatelet drug Drugs 0.000 claims 2
- 239000003633 blood substitute Substances 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 239000000480 calcium channel blocker Substances 0.000 claims 2
- 239000002872 contrast media Substances 0.000 claims 2
- 229960002768 dipyridamole Drugs 0.000 claims 2
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 229940088598 enzyme Drugs 0.000 claims 2
- 150000002270 gangliosides Chemical class 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 239000012216 imaging agent Substances 0.000 claims 2
- 239000003695 memory enhancer Substances 0.000 claims 2
- -1 neuroprotectives Substances 0.000 claims 2
- 239000002858 neurotransmitter agent Substances 0.000 claims 2
- 239000002664 nootropic agent Substances 0.000 claims 2
- 230000001777 nootropic effect Effects 0.000 claims 2
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims 2
- 239000002516 radical scavenger Substances 0.000 claims 2
- 229960005202 streptokinase Drugs 0.000 claims 2
- 230000002537 thrombolytic effect Effects 0.000 claims 2
- 229960005356 urokinase Drugs 0.000 claims 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 abstract 2
- 206010061216 Infarction Diseases 0.000 abstract 1
- 230000007574 infarction Effects 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 238000011084 recovery Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39926295A | 1995-03-06 | 1995-03-06 | |
| US08/603,102 US5872108A (en) | 1995-03-06 | 1996-02-20 | Reduction of infarct volume using citicoline |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL147477A true IL147477A (en) | 2010-02-17 |
Family
ID=23578854
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL147477A IL147477A (en) | 1995-03-06 | 1996-03-05 | Preparation of medication comprising citicoline together with a second pharmaceutical agent for protecting brain tissue from infraction following ischemia |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US5872108A (enExample) |
| KR (1) | KR19980702724A (enExample) |
| IL (1) | IL147477A (enExample) |
| IN (1) | IN182555B (enExample) |
| ZA (1) | ZA961791B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6732369B1 (en) * | 1995-10-02 | 2004-05-04 | Starsight Telecast, Inc. | Systems and methods for contextually linking television program information |
| WO1999033476A1 (en) * | 1997-12-24 | 1999-07-08 | Interneuron Pharmaceuticals, Inc. | Hyperhydrated citicoline, process and use |
| US6379882B1 (en) * | 1998-09-14 | 2002-04-30 | Elan Pharmaceuticals, Inc. | Method for selecting compounds for treating ischemia-related cellular damage |
| ES2169986B1 (es) * | 2000-03-14 | 2003-06-16 | Ferrer Int | Uso de cdp-colina para el tratamiento profilactico de la isquemia cerebral. |
| WO2001072779A1 (en) * | 2000-03-24 | 2001-10-04 | Duke University | Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto |
| US7235649B2 (en) * | 2000-03-24 | 2007-06-26 | Duke University | Isolated GRP94 ligand binding domain polypeptide and nucleic acid encoding same, and screening methods employing same |
| US7034054B2 (en) * | 2000-12-15 | 2006-04-25 | Galileo Pharmaceuticals, Inc. | Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols |
| WO2003100570A2 (en) * | 2002-05-23 | 2003-12-04 | New England Medical Center Hospitals, Inc. | Computer-assisted multi-dimensional patient selection |
| EP1750509A4 (en) * | 2004-05-13 | 2010-03-24 | Massachusetts Inst Technology | EFFECTS OF URIDINE ON DOPAMINE RELIEF |
| EA035619B1 (ru) | 2005-06-01 | 2020-07-16 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Композиции для использования в способе лечения митохондриальных нарушений |
| EP1986636B1 (en) | 2006-02-22 | 2013-04-24 | Edison Pharmaceuticals, Inc. | Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases |
| NO2470168T3 (enExample) | 2009-08-26 | 2018-06-30 | ||
| JP2011178687A (ja) * | 2010-02-26 | 2011-09-15 | Kochi Univ | 造血細胞移植に伴う疼痛の予防および／または治療剤 |
| US20140099262A1 (en) | 2011-06-01 | 2014-04-10 | Brain Watch Ltd. | Isotopically labeled cdp-choline and uses thereof |
| DK2857037T3 (da) | 2012-05-31 | 2019-07-22 | Univ Kinki | Middel til forebyggelse og/eller behandling af perifere neuropatiske smerter forårsaget af anticancerlægemiddel |
| EP3389646A1 (en) | 2015-12-17 | 2018-10-24 | BioElectron Technology Corporation | Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
| CA3112679A1 (en) | 2018-09-28 | 2020-04-02 | Asahi Kasei Pharma Corporation | Medicament for mitigating conditions and/or suppressing onset of peripheral neuropathy induced by anti-malignant tumor agent |
| US20250002559A1 (en) * | 2023-06-28 | 2025-01-02 | Pharmazz, Inc. | Pharmaceutical formulation for treatment of cerebral stroke |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5517769B2 (enExample) * | 1972-01-10 | 1980-05-14 | ||
| US4386078A (en) * | 1980-03-03 | 1983-05-31 | The Ohio State University Research Foundation | Therapeutic agents for preventing phospholipid degradation and free fatty acid proliferation |
| IT1207106B (it) * | 1980-04-18 | 1989-05-17 | Made Italiana Srl Ora Searle I | Preparazione farmaceutica contenente citidin disfofocolina assorbibile per via orale |
| JPS6043078B2 (ja) * | 1980-10-31 | 1985-09-26 | 株式会社興人 | シチジンジリン酸コリンの製法 |
| JPS57108099A (en) * | 1980-12-25 | 1982-07-05 | Kohjin Co Ltd | Preparation of choline cytidine diphosphate |
| JPS6043079B2 (ja) * | 1980-12-25 | 1985-09-26 | 株式会社興人 | シチジン二リン酸コリンの製造方法 |
-
1996
- 1996-02-20 US US08/603,102 patent/US5872108A/en not_active Expired - Lifetime
- 1996-03-05 ZA ZA961791A patent/ZA961791B/xx unknown
- 1996-03-05 IL IL147477A patent/IL147477A/en not_active IP Right Cessation
- 1996-03-06 KR KR1019970706131A patent/KR19980702724A/ko not_active Ceased
- 1996-03-06 IN IN347MA1996 patent/IN182555B/en unknown
-
1997
- 1997-03-18 US US08/820,244 patent/US5801160A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US5801160A (en) | 1998-09-01 |
| US5872108A (en) | 1999-02-16 |
| IN182555B (enExample) | 1999-05-01 |
| ZA961791B (en) | 1996-09-10 |
| KR19980702724A (ko) | 1998-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021107401A (ja) | カンナビノイドとｎ−アシルエタノールアミンの組み合わせ | |
| CA2492081A1 (en) | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders | |
| HUT51136A (en) | Process for producing pharmaceutical compositions for treating schisophreny, containing l-deprenil as active component | |
| AU9125798A (en) | Specific saccharide compositions and methods for treating alzheimer's disease and other amyloidoses | |
| DK0642335T3 (da) | Morphinsaltholdigt præparat med styret frigivelse | |
| WO1993017020A3 (en) | Therapeutic nucleosides | |
| SG52443A1 (en) | Methods and compositions for the treatment of disease with interferon while reducing sid effects | |
| YU209288A (en) | Process for producing compound for treating, which contains azelastin for use in nose and/or eye | |
| BR0311701A (pt) | Formulação de dosagem multiparticulada com liberação controlada de lamotrigina, composição farmacêutica, processo para a preparação de uma composição farmacêutica de lamotrigina, método para a redução da flutuação no pico e no depósito da concentração da droga no plasma do sangue de um paciente, método para melhorar a complacência de um paciente pela redução da frequência de dosagem para uma vez por dia, método para a ministração mais segura de lamotrigina, método para proporcionar uma concentração terapêutica de plasma de sangue de lamotrigina e uso da formulação | |
| FI935847A0 (fi) | L-DOPA-esterkompositioner | |
| CA2459470A1 (en) | Pharmaceutical composition comprising gabapentin or an analogue thereof and an .alpha.-aminoamide and its analgesic use | |
| TR200000149T2 (tr) | Serebral nörovasküler bozuklukların, müsküler baş ağrılarının önlenmesine yönelik kompozisyonlar | |
| CA2066403A1 (en) | Transmucosal dosage form | |
| HU213677B (en) | Pharmaceutical compositions for preventing and treating tumor diseases, and process for producing them | |
| LU88684I2 (fr) | Complexe lipidique d'amphotericine b ainsi que leurs dérivés pharmaceutiquement acceptables (abelcet ) | |
| RU95101385A (ru) | Продукты, содержащие g-csf и tnf связующие протеина | |
| US4849426A (en) | Method for treating actinic keratosis with cytotoxic agents | |
| BR9401199A (pt) | Preparados de medicamentos, processo para a preparação de um preparado de medicamento, processo para a preparação de uma formulação de medicamento. | |
| CA2314571A1 (en) | Methods and compositions for treating diseases and conditions of the eye | |
| MY124465A (en) | Reduction of infarct volume using citicoline | |
| Farris et al. | Cytarabine treatment of herpes simplex encephalitis | |
| HUP0001526A2 (hu) | Nukleozidok alkalmazása citokinekkel kapcsolatos megbetegedések kezelésére szolgáló gyógyszerkészítmények előállítására és gyógyszerkészítmények | |
| EP0387757B1 (en) | Use of 5'-deoxy-5'methylthioadenosine, S-adenosylmethionine and their salts in the preparation of pharmaceutical compositions favouring hair growth in subjects suffering from baldness | |
| BRPI0415322A (pt) | composição farmacêutica antiretroviral, processo para a preparação de uma composição farmacêutica antiretroviral, método para reduzir a carga de consumo de pìlulas para um paciente, método para aumentar a meia-vida in vivo de lamivudina e de zidovudina enquanto não afetando a meia-vida de nevirapina | |
| EP0615750A2 (en) | Treatment of a group of related disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| EXP | Patent expired |